title: Reply to X. Qi et al.
authors: Icahn School of Medicine at Mount Sinai, New York, NY; and Institut d'investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
authors: Josep M
authors: JM
authors: Llovet
authors: Philip J
authors: PJ
authors: Johnson
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D016879:Salvage Therapy; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D014227:Triazines; D009536:Niacinamide; D000409:Alanine